436 related articles for article (PubMed ID: 31493197)
21. Contribution of neuroimaging to the diagnosis of Alzheimer's disease and vascular dementia.
Román G; Pascual B
Arch Med Res; 2012 Nov; 43(8):671-6. PubMed ID: 23142262
[TBL] [Abstract][Full Text] [Related]
22. Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer's disease based on the A/T(N) research framework.
Wang Y; Zhang Y; Yu E
Clin Neurol Neurosurg; 2024 Jan; 236():108071. PubMed ID: 38043158
[TBL] [Abstract][Full Text] [Related]
23. Alzheimer's disease neuroimaging.
Whitwell JL
Curr Opin Neurol; 2018 Aug; 31(4):396-404. PubMed ID: 29762152
[TBL] [Abstract][Full Text] [Related]
24. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
[TBL] [Abstract][Full Text] [Related]
25. Secondary prevention of Alzheimer's dementia: neuroimaging contributions.
Ten Kate M; Ingala S; Schwarz AJ; Fox NC; Chételat G; van Berckel BNM; Ewers M; Foley C; Gispert JD; Hill D; Irizarry MC; Lammertsma AA; Molinuevo JL; Ritchie C; Scheltens P; Schmidt ME; Visser PJ; Waldman A; Wardlaw J; Haller S; Barkhof F
Alzheimers Res Ther; 2018 Oct; 10(1):112. PubMed ID: 30376881
[TBL] [Abstract][Full Text] [Related]
26. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
27. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
28. Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease.
Whitwell JL; Graff-Radford J; Tosakulwong N; Weigand SD; Machulda MM; Senjem ML; Spychalla AJ; Vemuri P; Jones DT; Drubach DA; Knopman DS; Boeve BF; Ertekin-Taner N; Petersen RC; Lowe VJ; Jack CR; Josephs KA
Alzheimers Dement; 2018 Aug; 14(8):1005-1014. PubMed ID: 29605222
[TBL] [Abstract][Full Text] [Related]
29. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
30. Alzheimer's Dementia: The Emerging Role of Positron Emission Tomography.
Tripathi SM; Murray AD
Neuroscientist; 2022 Oct; 28(5):507-519. PubMed ID: 33660556
[TBL] [Abstract][Full Text] [Related]
31. Tau PET: the next frontier in molecular imaging of dementia.
Xia C; Dickerson BC
Int Psychogeriatr; 2016 Sep; 28(9):1403-6. PubMed ID: 27334648
[TBL] [Abstract][Full Text] [Related]
32. Applied multimodal diagnostics in a case of presenile dementia.
Schönecker S; Brendel M; Huber M; Vollmar C; Huppertz HJ; Teipel S; Okamura N; Levin J; Rominger A; Danek A
BMC Neurol; 2016 Aug; 16():131. PubMed ID: 27506761
[TBL] [Abstract][Full Text] [Related]
33. Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring.
van Oostveen WM; de Lange ECM
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672696
[TBL] [Abstract][Full Text] [Related]
34. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.
Brier MR; Gordon B; Friedrichsen K; McCarthy J; Stern A; Christensen J; Owen C; Aldea P; Su Y; Hassenstab J; Cairns NJ; Holtzman DM; Fagan AM; Morris JC; Benzinger TL; Ances BM
Sci Transl Med; 2016 May; 8(338):338ra66. PubMed ID: 27169802
[TBL] [Abstract][Full Text] [Related]
35. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
[TBL] [Abstract][Full Text] [Related]
36. Molecular targets in the rational design of AD specific PET tracers: tau or amyloid aggregates?
Rojo LE; Gaspar PA; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):652-8. PubMed ID: 21605040
[TBL] [Abstract][Full Text] [Related]
37. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O;
Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982
[TBL] [Abstract][Full Text] [Related]
38. Future Directions in Imaging Neurodegeneration.
Masdeu JC
Curr Neurol Neurosci Rep; 2017 Jan; 17(1):9. PubMed ID: 28210978
[TBL] [Abstract][Full Text] [Related]
39. Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future.
Ariza M; Kolb HC; Moechars D; Rombouts F; Andrés JI
J Med Chem; 2015 Jun; 58(11):4365-82. PubMed ID: 25671691
[TBL] [Abstract][Full Text] [Related]
40. PET of brain amyloid and tau in mild cognitive impairment.
Small GW; Kepe V; Ercoli LM; Siddarth P; Bookheimer SY; Miller KJ; Lavretsky H; Burggren AC; Cole GM; Vinters HV; Thompson PM; Huang SC; Satyamurthy N; Phelps ME; Barrio JR
N Engl J Med; 2006 Dec; 355(25):2652-63. PubMed ID: 17182990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
